Th1-related disease development during omalizumab treatment: Two cases with severe asthma

Allergol Int. 2018 Jul;67(3):405-407. doi: 10.1016/j.alit.2017.10.008. Epub 2017 Nov 27.

¹ Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
² Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan.
³ Department of Pathology, Sagamihara National Hospital, Sagamihara, Japan.
⁴ Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
⁵ Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan. Electronic address: m-taniguchi@sagamihara-hosp.gr.jp.

No abstract available

Publication types